

## DAFTAR PUSTAKA

1. Chen VW, Ruiz BA, Hsieh MC, Wu XC, Ries L, Lewis DR. Analysis of Stage and Clinical/Prognostic Factors for Lung Cancer from SEER Registries: AJCC Staging and Collaborative Stage Data Collection System. *cancer*. 2014: 3781–92.
2. Crawford J, Denduluri N, Patt D, Jiao X, Morrow PK, Garcia J, et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. *springer*. 2019; 28: 925–32.
3. Yin JY, Li X, Li XP, Xiao L, Zheng W, Chen J, et al. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients. *Cancer Lett*. 2016;377(1):65–73.
4. Min HY, Lee HY. Mechanisms of resistance to chemotherapy in non-small cell lung cancer. *Arch Pharm Res*. 2021;44(2):146–64.
5. Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. *Nat Rev Cancer*. 2021;21(6):345–59.
6. Shoji F. Clinical impact of the systemic immune-inflammation index in non-small cell lung cancer patients. *Ann Transl Med*. 2020;8(11):668–73.
7. Hu M, Xu Q, Yang S, Han S, Zhu Y, Lin Q, et al. Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study. *Ann Transl Med*. 2020;8(20):1310–19.
8. Jiang S, Wang S, Wang Q, Deng C, Feng Y, Ma F, et al. Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs. *Cancer Manag Res*. 2021;13:1315–22.
9. Li S, Yang Z, Du H, Zhang W, Che G, Liu L. Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study. *ANZ J Surg*. 2019 ;89(11):507–13.

10. Jusuf A, Wibawanto A, Icksan AG, Syahrudin E, Juniarti, Endardjo S. Kanker paru. 1st ed. Syahrudin E, Jusuf A, editors. Jakarta: UI-Press; 2018: h.1–37.
11. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. *J Thorac Oncol*. 2021;17(3): 362–87.
12. Alatas MF, Putra AC, Andarini S, Sutoyo DK LT. Dasar-dasar Diagnosis Kanker Paru. Jakarta: UI-Press; 2017. h. 113–25.
13. Tan Z, Xue H, Sun Y, Zhang C, Song Y, Qi Y. The Role of Tumor Inflammatory Microenvironment in Lung Cancer. *Front Pharmacol*. 2021;12: 1–13.
14. Zhou J, Liu H, Jiang S, Wang W. Role of tumor-associated neutrophils in lung cancer (Review). *Oncol Lett*. 2023 Jan 1;25(2):1–9.
15. Wislez M, Antoine M, Rabbe N, Gounant V, Poulot V, Lavolé A, et al. Neutrophils promote aerogenous spread of lung adenocarcinoma with bronchioloalveolar carcinoma features. *Clin Cancer Res*. 2007;13(12):3518–27.
16. Brostjan C, Oehler R. The role of neutrophil death in chronic inflammation and cancer. *Springer Nature*; 2020;6(26):1–8.
17. Zheng H, Yambayev I, Shevtsov A, Burks EJ. Narrative review of the pathologic assessment of immune response in lung cancer. *AME Med J*. 2021;6(10): 1–7.
18. Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. *J Leukoc Biol*. 2019;106(2):309–22.
19. Wang Y, Huang D, Xu WY, Wang YW, Che GW. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Non-Small Cell Lung Cancer: A Meta-Analysis. *Oncol Res Treat*. 2019;42(10):523–30.
20. Lababede O, Meziane MA. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. *Oncologist*. 2018;23(7):844–8.
21. Jusuf A, hudoyo A SE. Pengobatan Kanker Paru. Jakarta: perhimpunan dokter paru indonesia; 2019. h. 1–162.

22. Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. *J Clin Oncol*. 2008; 26(1):54–9.
23. Syahrudin E, Marlina N, Hudoyo A, Persahabatan S. Efikasi dan Toksisitas Rejimen Sisplatin + Etoposid untuk Kemoterapi Kanker Paru Jenis Karsinoma Bukan Sel Kecil (KPKBSK) Stage Lanjut Efficacy and Toxicity Chemotherapy With Cisplatin + Etoposide Regiment in Advanced Stage non-Small Cell Lung Cancer. *J Respir Indo*. 2012;32(1):25–35.
24. Chen J, Shao J, Zhang X, Wei S, Cai H, Wang G. Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer. *Ann Transl Med*. 2022;10(5):253–66.
25. Azam F, Latif MF, Farooq A, Tirmazy SH, Alshahrani S, Bashir S, et al. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. *Case Rep Oncol*. 2019;12(3):728–36.
26. Syahrudin E, Zaini J, Soehardiman D, Anwidyaningsih W, Icksan AG, Mety SH et al. staging PDPI 2019. Jakarta: Perhimpunan Dokter Paru indonesia; 2019. h. 1–31.
27. Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. *Clin Exp Pharmacol Physiol*. 2016;43(8):723–37.
28. Chen SH, Chang JY. New insights into mechanisms of cisplatin resistance: From tumor cell to microenvironment. *Int J Mol Sci*. 2019;20(17):2–21.
29. Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1 $\alpha$  gene. *Cancer Chemother Pharmacol*. 2006;58(6):776–84.
30. Huang WC, Kuo KT, Wang CH, Yeh CT, Wang Y. Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages

via the Src/CD155/MIF functional pathway. *J Exp Clin Cancer Res.* 2019;38(1):1–17.

31. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. *Br J Cancer.* 2011;104(8):1288–91.
32. Dong J, Sun Q, Pan Y, Lu N, Han X, Zhou Q. Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy. *BMC Cancer.* 2021;21(1):1–9.
33. Nayak R RS. *Rapid Review of Hematology.* New Delhi: Jaypee Brothers Medical Publishers; 2014. p. 50–110.
34. Baker RG, Hayden MS, Ghosh S. NF- $\kappa$ B, inflammation, and metabolic disease. *Cell Metab.* 2011;13(1):11–22.
35. Wei L, Xie H, Yan P. Prognostic value of the systemic inflammation response index in human malignancy: A meta-analysis. *Medicine (Baltimore).* 2020;99(50): 23486–9.
36. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell.* 2010;140(6): 883–99.
37. Gregory AD, Houghton AMG. Tumor-associated neutrophils: new targets for cancer therapy. *Cancer Res.* 2011;71(7):2411–6.
38. Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, et al. Tumor-Associated Macrophages Produce *Interleukin 6* and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. *Gastroenterology.* 2014;147(6):1393–5.
39. Kramarrow AE. Health of Former Cigarette Smokers Aged 65 and Over: United States, 2018. *National Health Statistics Reports.* 2020; 145(7): 1–11.
40. Cao M, Chen W. Epidemiology of lung cancer in China. Vol. 10, *Thoracic Cancer.* John Wiley and Sons Inc; 2019. p. 3–7.
41. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Vol. 25, *Wspolczesna Onkologia.* Termedia Publishing House Ltd.; 2021. p. 45–52.

42. Andarini S, Syahrudin E, Aditya N, Zaini J, Kurniawan FD, Ermayanti S, et al. Indonesian Society of Respiriology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia. *Jurnal Respiriologi Indonesia*. 2023;43(2):144–50.
43. Andriani R, Rosewitasari J, Hanif MA, Mulawarman A, Kurniawati SA, Fachri A. Factors Affecting 2-Year Survival in Patients With Non–Small Cell Lung Cancer Brain Metastases: Evidence from Indonesia’s National Cancer Center, Jakarta, Indonesia. *Clin Med Insights Oncol*. 2023;17:1–8.
44. Ermayanti S, Afriani A, Nikmawati S, Russilawati R, Medison I, Suyastri S. Gender Disparities in Their Effects on Characteristics and Prognostics of Lung Cancer Patients in Pulmonary Ward of Dr. M Djamil Hospital, Padang. *Respirologi Indones*. 2021;41(4):245–51.
45. Ernawati Y, Ermayanti S, Herman D, Russilawati R. Faktor Risiko Kanker Paru pada Perempuan yang Dirawat di Bagian Paru RSUP Dr. M. Djamil Padang dan RSUD Solok: Penelitian Case Control. *J Kesehat Andalas*. 2019;8(2):1–8.
46. Magkouta S, Glynos K, Pappas A, Papapetropoulos A, Kalomenidis I. Effect of smoking on experimental malignant pleural effusion. *European Respiratory Journal*. 2015;46 :1–8.
47. Wang BY, Huang JY, Chen HC, Lin CH, Lin SH, Hung WH, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. *J Cancer Res Clin Oncol*. 2020;146(1):43–52.
48. Suraya A, Nowak D, Sulistomo AW, Icksan AG, Berger U, Syahrudin E, et al. Excess Risk of Lung Cancer Among Agriculture and Construction Workers in Indonesia. *Ann Glob Health*. 2021;87(1):1–14.
49. Sutandyo N, Suratman E. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia. *Acta Med Indones*. 2018;50(4):291–8.
50. Zhou Y, Dai M, Zhang Z. Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A Meta-Analysis. *Frontiers in Oncology*. 2022; 12 (814727): 1–10.

51. Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M, et al. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. *JAMA Netw Open*. 2021; 4(2):1–20.
52. Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, et al. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. *Lancet Healthy Longev*. 2021;2(12):791–800.
53. Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. *Lung Cancer*. 2008; 59(1):1–11.
54. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. *Nutr J*. 2010;9(1): 1–16.
55. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. *Eur J Cancer*. 2009;45(11):1950–8.
56. Berardi R, Santoni M, Rinaldi S, Bower M, Tiberi M, Morgese F, et al. Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. *Ann Transl Med*. 2019;7(20):572–5.
57. Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, et al. The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. *BMC Cancer*. 2015;15(1):1–8.
58. Banerjee R, Roxin G, Eliasziw M, Joseph K, MacLean A, Buie WD, et al. The prognostic significance of pretreatment leukocytosis in patients with

- anal cancer treated with radical chemoradiotherapy or radiotherapy. *Dis Colon Rectum*. 2013;56(9):1036–42.
59. Valero C, Pardo L, López M, García J, Camacho M, Quer M, et al. Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer. *Head Neck*. 2017;39(2):219–26.
60. Schernberg A, Mezquita L, Boros A, Botticella A, Caramella C, Besse B, et al. Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer. *PLoS One*. 2018;13(10):1–14.
61. Spiegel A, Brooks MW, Houshyar S, Reinhardt F, Ardolino M, Fessler E, et al. Neutrophils suppress intraluminal NK-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. *Cancer Discov*. 2016;6(6):630–5.
62. Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. *Nat Rev Immunol*. 2021;21(8):485–98.
63. Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer. *World J Surg Oncol*. 2015;13(1):1–8.
64. Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, Zogopoulos G, et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. *Pancreatology*. 2020;20(2):254–64.
65. Kucuk A, Ozkan EE, Eskici Oztep S, Mertsoylu H, Pehlivan B, Selek U, et al. The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. *J Oncol*. 2020; 20:1–8.
66. Wang L, Qin X, Zhang Y, Xue S, Song X. The prognostic predictive value of systemic immune index and systemic inflammatory response index in

nasopharyngeal carcinoma: A systematic review and meta-analysis. *FrontOncol.* 2023;13:1–11.

